Heron Therapeutics, Inc. (NASDAQ:HRTX) Receives Average Rating of “Hold” from Analysts

Shares of Heron Therapeutics, Inc. (NASDAQ:HRTX) have been given an average rating of “Hold” by the five brokerages that are presently covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and one has issued a buy recommendation on the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $2.00.

HRTX has been the subject of a number of recent research reports. Wall Street Zen upgraded shares of Heron Therapeutics to a “sell” rating in a research note on Saturday, August 8th. Zacks Research upgraded shares of Heron Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Monday, August 3rd. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Heron Therapeutics in a report on Friday, July 17th. HC Wainwright downgraded shares of Heron Therapeutics from a “buy” rating to a “neutral” rating in a research note on Tuesday, August 11th. Finally, Needham & Company LLC lowered Heron Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, June 2nd.

Heron Therapeutics Trading Down 0.3%

NASDAQ:HRTX opened at $0.29 on Friday. The company has a market capitalization of $55.06 million, a PE ratio of -1.53 and a beta of 1.61. Heron Therapeutics has a 52-week low of $0.26 and a 52-week high of $1.57. The stock’s 50 day moving average price is $0.37 and its 200 day moving average price is $0.62. The company has a quick ratio of 1.51, a current ratio of 2.49 and a debt-to-equity ratio of 24.35.

Heron Therapeutics (NASDAQ:HRTX) last issued its quarterly earnings data on Monday, August 10th. The biotechnology company reported ($0.03) earnings per share for the quarter. The firm had revenue of $37.67 million during the quarter, compared to analysts’ expectations of $42.19 million. Heron Therapeutics had a negative net margin of 22.52% and a negative return on equity of 293.02%. On average, research analysts anticipate that Heron Therapeutics will post -0.14 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of HRTX. Clearline Capital LP increased its holdings in shares of Heron Therapeutics by 26.0% in the fourth quarter. Clearline Capital LP now owns 12,235,239 shares of the biotechnology company’s stock valued at $15,906,000 after purchasing an additional 2,522,712 shares during the period. BlackRock Inc. purchased a new stake in shares of Heron Therapeutics during the second quarter worth approximately $4,503,000. Orbimed Advisors LLC acquired a new stake in shares of Heron Therapeutics during the first quarter worth $7,855,000. Tejara Capital Ltd acquired a new stake in shares of Heron Therapeutics during the second quarter worth $2,779,000. Finally, Pale Fire Capital SE grew its position in Heron Therapeutics by 84.8% in the 1st quarter. Pale Fire Capital SE now owns 2,716,328 shares of the biotechnology company’s stock valued at $2,173,000 after buying an additional 1,246,673 shares during the last quarter. 80.01% of the stock is currently owned by hedge funds and other institutional investors.

About Heron Therapeutics

Heron Therapeutics, Inc is a commercial-stage biotechnology company focused on developing and commercializing medicines for acute care and oncology. The company uses its Biochronomer drug-delivery platform to formulate therapies intended to provide sustained drug release and improve treatment convenience, efficacy, or tolerability.

Heron’s portfolio includes ZYNRELEF, an extended-release solution combining bupivacaine and meloxicam for the management of postsurgical pain. The company also markets APONVIE, an injectable formulation of aprepitant used to help prevent postoperative nausea and vomiting in adults.